MM+M Women of Distinction honoree, announced Monday morning that she has joined Medtronic Diabetes as its chief marketing ...

Beam Therapeutics and Verve Therapeutics have each built their lead candidates on a technique billed as a safer alternative ...

Ribonucleic acid (RNA) molecules may be best known for their job ferrying the genetic information encoded in DNA to a cell's ...

Moderna (NasdaqGS:MRNA) recently reported a decline in revenue for Q1 2025, but managed to reduce its net loss and improve its loss per share. Despite this, the company's stock price was ...

Following the COVID-19 pandemic, mRNA-based vaccines have been shown to provide rapid and precise immune responses, however, this technology has much wider applications. Many leading pharma and ...

This manuscript characterizes a mutated clone of RNA polymerase I in yeast, referred to as SuperPol, to understand the mechanisms of RNA polymerase I elongation and termination. The authors present ...

A “tolerability issue” caused a temporary pause to an early stage study involving a closely watched, inhaled, mRNA-based therapy for cystic fibrosis, the company said. Vertex shares fell 3% ...

Moderna – at the moment embroiled in a patent dispute with Pfizer and BioNTech over mRNA intellectual property – is also testing a vaccine that combines COVID-19 and flu in a single jab in a ...

The latest price target for Moderna (NASDAQ:MRNA) was reported by UBS on May 2, 2025. The analyst firm set a price target for $70.00 expecting MRNA to rise to within 12 months (a possible 152.71% ...